CIPLA vs STAR: Stock Comparison

Cipla Ltd vs Strides Pharma Science Limited

Live data: 22 July 2026, 2:34 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a higher dividend yield, lower leverage and a higher net margin, while Strides Pharma Science Limited shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Strides Pharma Science Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 4 of 13 scored metrics and STAR on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹9,513 Cr
P/E Ratio
STAR has a lower P/E
17.37x vs 29.83x
P/B Ratio
STAR has a lower P/B
3.11x vs 3.36x
EPS
STAR has higher earnings per share
₹60.31 vs ₹48.01
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.37%
Revenue Growth (TTM YoY)
STAR has faster revenue growth
11.2% vs -2.1%
EPS Growth (TTM YoY)
STAR has faster EPS growth
54.4% vs -54.6%
Qtr Sales Growth
STAR has stronger quarterly sales growth
11.2% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLASTAR
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLASTAR
Live Price₹1,410.9₹1,031.6
Day Change-1.51%-1.87%
Volume12.88 L2.03 L
52-Week High₹1,673₹1,231
52-Week Low₹1,165.7₹768.65
Distance from 52W High-15.67%-16.2%

Valuation

MetricCIPLASTAR
Market Cap₹1.14 L Cr₹9,513 Cr
P/E Ratio29.83x17.37x
P/B Ratio3.36x3.11x
EPS₹48.01₹60.31
Book Value₹426.25₹337.09
Dividend Yield0.9%0.37%

Growth

MetricCIPLASTAR
Revenue Growth (TTM YoY)-2.1%11.2%
EPS Growth (TTM YoY)-54.6%54.4%
Qtr Sales Growth-2.8%11.2%
Qtr Profit Growth-54.6%28.1%

Profitability & Leverage

MetricCIPLASTAR
ROE11.6%20.4%
ROCE15.5%18.6%
Net Margin13.96%10.58%
Operating Margin20.9%19%
Debt to Equity0.02x0.57x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLASTAR
Promoter Holding9.17%27.91% 0.05 pp
FII Holding22.56% 1.37 pp28.68% 0.84 pp
DII Holding31.97% 1.25 pp14.45% 1.43 pp
Public Holding16.25% 0.12 pp28.95% 0.64 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Strides Pharma Science Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.